secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardio Diagnostics Holdings, Inc. (CDIO)
CIK:        0001870144
Form:       8-K
Filed at:   2022-09-21T23:59:59+00:00
Accession:  0001079973-22-001136
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardio Diagnostics secures U.S. patent for cardiovascular disease detection technology
--------------------------------------------------------------------------------

- U.S. Patent No. 11,414,704 issued by USPTO to University of Iowa Research Foundation (UIRF), exclusively licensed to Cardio Diagnostics.
- Patent covers compositions and methods for detecting predisposition to cardiovascular disease; co-invented by Cardio founders/CEO Meesha Dogan and CMO Robert Philibert.
- The patent technology is used in Cardio's flagship product Epi+Gen CHD, a three-year symptomatic CHD risk assessment test introduced in 2021.
- Cardio Diagnostics is merging with Mana Capital Acquisition Corp. (Nasdaq: MAAQU) in a previously announced business combination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870144/000107997322001136/0001079973-22-001136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870144/000107997322001136/mana_8k-092022.htm
  HTML page:      https://secwatch.observer/filing/0001079973-22-001136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer